Transthyretin Amyloidosis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Transthyretin Amyloidosis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Transthyretin amyloidosis is a rare inherited and slowly progressive disease characterized by abnormal buildup of deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Two main type of transthyretin amyloidosis includes hereditary transthyretin amyloidosis and wild type transthyretin amyloidosis. Hereditary transthyretin amyloidosis is further divided into polyneuropathy, cardiomyopathy, and mixed type.
Diagnosis of transthyretin amyloidosis includes approaches such as imaging, histopathology, and molecular and genetic testing. Cardiac biomarkers such as N-terminal fragment of brain natriuretic peptide (NT-proBNP) and troponin are present in abnormally high concentrations in the heart, following amyloid deposits that can be tested for diagnosis of the disease. Genetic testing for transthyretin gene mutations is performed in case of familial transthyretin amyloidosis diagnosis.
Market Dynamics
Approvals and launches of novel therapies for the treatment of transthyretin amyloidosis is expected to be a major factor driving the market growth over the forecast period. In October 2018, Eidos Therapeutics, Inc. received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its drug candidate AG10, indicated for the treatment of ATTR.
In October 2018, Ionis Pharmaceuticals, Inc. and its Akcea Therapeutics Inc., received approval for its drug TEGSEDITM (inotersen injection) in Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)
Furthermore, increasing number under development drugs for the treatment of transthyretin amyloidosis are expected to gain approval in the near future. Therefore, presence of such robust pipeline is expected to boost the market growth. For instance, GlaxoSmithKline plc. a pharmaceutical company, is developing dezamizumab (2398852)† +2315698†, a combination of GSK2398852 (anti-SAP mAb) and GSK2315698 (CPHPC) for the treatment of amyloidosis. Currently, the product is under phase 2 clinical trial.
Key features of the study:
This report provides in-depth analysis of the global transthyretin amyloidosis treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
It profiles key players in the global transthyretin amyloidosis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key companies covered as a part of this study include, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global transthyretin amyloidosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global transthyretin amyloidosis treatment market
Detailed Segmentation:
Global Transthyretin Amyloidosis Treatment Market, by Drug Type:
Tafamidis (Vyndaqel)
Patisiran (ONPATTRO)
Inotersen (TEGSEDI)
Others
Global Transthyretin Amyloidosis Treatment Market, by Disease Type:
Hereditary Transthyretin Amyloidosis
Polyneuropathy
Cardiomyopathy
Mixed Type
Wild Type Amyloidosis
Global Transthyretin Amyloidosis Treatment Market, by Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies
Global Transthyretin Amyloidosis Treatment Market, By Geography:
North America
By Drug Type:
Tafamidis (Vyndaqel)
Patisiran (ONPATTRO)
Inotersen (TEGSEDI)
Others
By Disease Type:
Hereditary Transthyretin Amyloidosis
Polyneuropathy
Cardiomyopathy
Mixed Type
Wild Type Amyloidosis
By Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Europe
By Drug Type:
Tafamidis (Vyndaqel)
Patisiran (ONPATTRO)
Inotersen (TEGSEDI)
Others
By Disease Type:
Hereditary Transthyretin Amyloidosis
Polyneuropathy
Cardiomyopathy
Mixed Type
Wild Type Amyloidosis
By Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type:
Tafamidis (Vyndaqel)
Patisiran (ONPATTRO)
Inotersen (TEGSEDI)
Others
By Disease Type:
Hereditary Transthyretin Amyloidosis
Polyneuropathy
Cardiomyopathy
Mixed Type
Wild Type Amyloidosis
By Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Drug Type:
Tafamidis (Vyndaqel)
Patisiran (ONPATTRO)
Inotersen (TEGSEDI)
Others
By Disease Type:
Hereditary Transthyretin Amyloidosis
Wild Type Amyloidosis
By Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
By Drug Type:
Tafamidis (Vyndaqel)
Patisiran (ONPATTRO)
Inotersen (TEGSEDI)
Others
By Disease Type:
Hereditary Transthyretin Amyloidosis
Polyneuropathy
Cardiomyopathy
Mixed Type
Wild Type Amyloidosis
By Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Type:
Tafamidis (Vyndaqel)
Patisiran (ONPATTRO)
Inotersen (TEGSEDI)
Others
By Disease Type:
Hereditary Transthyretin Amyloidosis
Wild Type Amyloidosis
By Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Central Africa
South Africa
North Africa
North Africa
Company Profiles
Alnylam Pharmaceuticals, Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Ionis Pharmaceuticals, Inc.
Pfizer, Inc.
Eidos Therapeutics, Inc.
Akcea Therapeutics, Inc.
Prothena Corporation Plc.
GlaxoSmithKline Plc.
SOM Innovation Biotech, S.L.
“*” marked represents similar segmentation in other categories in the respective section.